We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Date
Sponsor content
4 result(s) found, displaying 1 to 4
-
Australian public assessment report (AusPar)New AusPAR for Empaveli (pegcetacoplan) for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria.
-
Prescription medicine decision summaryTGA decision: Empaveli (pegcetacoplan) is approved to treat adult patients with paroxysmal nocturnal haemoglobinuria (PNH).
-
Prescription medicine registrationActive ingredients: pegcetacoplan.
-
Prescription medicine registrationActive ingredients: pegcetacoplan.